Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $213.92 billion. The enterprise value is $226.44 billion.
| Market Cap | 213.92B |
| Enterprise Value | 226.44B |
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.57% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.57% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.19B |
Valuation Ratios
The trailing PE ratio is 12.41 and the forward PE ratio is 12.48.
| PE Ratio | 12.41 |
| Forward PE | 12.48 |
| PS Ratio | 4.36 |
| Forward PS | 0.86 |
| PB Ratio | 8.08 |
| P/TBV Ratio | 22.57 |
| P/FCF Ratio | 20.97 |
| P/OCF Ratio | 11.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.03, with an EV/FCF ratio of 22.19.
| EV / Earnings | 12.95 |
| EV / Sales | 4.61 |
| EV / EBITDA | 9.03 |
| EV / EBIT | 9.68 |
| EV / FCF | 22.19 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 0.59.
| Current Ratio | 0.78 |
| Quick Ratio | 0.50 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 0.62 |
| Debt / FCF | 1.53 |
| Interest Coverage | 17.27 |
Financial Efficiency
Return on equity (ROE) is 79.17% and return on invested capital (ROIC) is 42.53%.
| Return on Equity (ROE) | 79.17% |
| Return on Assets (ROA) | 21.82% |
| Return on Invested Capital (ROIC) | 42.53% |
| Return on Capital Employed (ROCE) | 54.12% |
| Revenue Per Employee | $634,901 |
| Profits Per Employee | $226,061 |
| Employee Count | 77,349 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.20 |
Taxes
In the past 12 months, Novo Nordisk has paid $4.68 billion in taxes.
| Income Tax | 4.68B |
| Effective Tax Rate | 21.10% |
Stock Price Statistics
The stock price has decreased by -62.53% in the last 52 weeks. The beta is 0.27, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -62.53% |
| 50-Day Moving Average | 67.44 |
| 200-Day Moving Average | 81.29 |
| Relative Strength Index (RSI) | 30.99 |
| Average Volume (20 Days) | 23,899,011 |
Short Selling Information
The latest short interest is 23.58 million, so 0.70% of the outstanding shares have been sold short.
| Short Interest | 23.58M |
| Short Previous Month | 26.61M |
| Short % of Shares Out | 0.70% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.04 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $49.11 billion and earned $17.49 billion in profits. Earnings per share was $3.93.
| Revenue | 49.11B |
| Gross Profit | 41.38B |
| Operating Income | 23.40B |
| Pretax Income | n/a |
| Net Income | 17.49B |
| EBITDA | 25.07B |
| EBIT | 23.40B |
| Earnings Per Share (EPS) | $3.93 |
Balance Sheet
The company has $2.98 billion in cash and $15.63 billion in debt, giving a net cash position of -$12.65 billion or -$2.85 per share.
| Cash & Cash Equivalents | 2.98B |
| Total Debt | 15.63B |
| Net Cash | -12.65B |
| Net Cash Per Share | -$2.85 |
| Equity (Book Value) | 26.46B |
| Book Value Per Share | 5.95 |
| Working Capital | -7.06B |
Cash Flow
In the last 12 months, operating cash flow was $19.13 billion and capital expenditures -$8.86 billion, giving a free cash flow of $10.20 billion.
| Operating Cash Flow | 19.13B |
| Capital Expenditures | -8.86B |
| Free Cash Flow | 10.20B |
| FCF Per Share | $2.30 |
Margins
Gross margin is 84.26%, with operating and profit margins of 47.65% and 35.61%.
| Gross Margin | 84.26% |
| Operating Margin | 47.65% |
| Pretax Margin | 45.13% |
| Profit Margin | 35.61% |
| EBITDA Margin | 51.06% |
| EBIT Margin | 47.65% |
| FCF Margin | 20.78% |
Dividends & Yields
This stock pays an annual dividend of $1.18, which amounts to a dividend yield of 2.42%.
| Dividend Per Share | $1.18 |
| Dividend Yield | 2.42% |
| Dividend Growth (YoY) | 21.07% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 34.73% |
| Buyback Yield | 0.57% |
| Shareholder Yield | 2.99% |
| Earnings Yield | 8.17% |
| FCF Yield | 4.77% |
Analyst Forecast
The average price target for Novo Nordisk is $112.00, which is 129.70% higher than the current price. The consensus rating is "Buy".
| Price Target | $112.00 |
| Price Target Difference | 129.70% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 7.82 and a Piotroski F-Score of 4.
| Altman Z-Score | 7.82 |
| Piotroski F-Score | 4 |